Low dosage may be behind low efficacy of CureVac vaccine -study leader - Reuters

6:26am PDT - June 17th, 2021    arsenal - Reuters

The low dosage might be a key reason why CureVac's (5CV.DE) COVID-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said on Thursday.